Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
The Christie NHS Foundation Trust, Manchester, UK.
Clin Oncol (R Coll Radiol). 2022 Nov;34(11):733-740. doi: 10.1016/j.clon.2022.08.027. Epub 2022 Aug 30.
Stereotactic ablative radiotherapy (SABR) is an important curative-intent treatment option for early-stage non-small cell lung cancer. It offers good cancer control without invasive surgery and has become the standard of care for medically inoperable patients. The literature on SABR for early-stage non-small cell lung cancer is substantial and continues to grow. However, there remain areas of controversy where data are limited - notably the use of SABR in medically operable patients. Other areas of some debate include the treatment of central/ultra-central and large (>5 cm) lesions, as well as treatment with co-existing interstitial lung disease. This review article provides an overview of the current literature together with a discussion of future directions.
立体定向消融放疗（SABR）是早期非小细胞肺癌的一种重要的有治愈意图的治疗选择。它提供了无需侵入性手术的良好癌症控制效果，并且已成为不能手术的患者的治疗标准。关于早期非小细胞肺癌的 SABR 文献很多，并且还在不断增加。但是，在数据有限的情况下，仍然存在一些有争议的领域 - 特别是在可手术的患者中使用 SABR。其他一些存在争议的领域包括中央/超中央和大（> 5cm）病变的治疗，以及合并间质性肺疾病的治疗。本文综述了当前的文献，并讨论了未来的方向。
